Trainee Research

(001) A Comparison of Obinutuzumab Plus Venetoclax Sequencing on Tumor Lysis and Associated Outcomes in Patients with Chronic Lymphocytic Leukemia

(002) A Qualitative Assessment of Professional Distress among Pharmacy Residents and Clinical Pharmacist Specialists at a Dedicated Cancer Center

(003) A retrospective comparison of AML17 and APL0406 regimens for low-risk acute promyelocytic leukemia

(004) A Retrospective Study Evaluating High-Dose Methotrexate Clearance, with a Focus on Characteristics Associated with Faster Clearance

(005) A Single-Institution Experience with Gemcitabine Plus Vinorelbine Chemotherapy in Advanced Sarcomas

(006) Advancing Ambulatory Oncology Pharmacy Practice

(007) Adverse Event Outcomes When Changing Front-line Asparaginase Products for Leukemia Patients At A Children’s Hospital

(008) An Evaluation of the Relationship Between Asparaginase Dose, Pharmacokinetics, and Toxicities Among Pediatric Acute Lymphoblastic Leukemia and Lymphoma Patients

(009) Analysis of Early Discontinuations, Dose Adjustments, and Adverse Events in Patients with HR+, HER2- Early-Stage Breast Cancer Receiving Adjuvant Abemaciclib with Endocrine Therapy

(010) Analysis of Pharmacist Integration in the Prior Authorization Practice Model in an Outpatient Cancer Center

(011) Asparaginase Therapeutic Drug Monitoring: Utility of Peak and 7-Day Serum Asparaginase Activity Levels as Surrogate Markers for Day 14 Serum Asparaginase Activity

(012) Assess the Safety and Efficacy of Blinatumomab and Inotuzumab with Chemotherapy in Relapsed and Refractory Ph-negative B-cell Acute Lymphoblastic Leukemia at an Academic Medical Center

(013) Assessing Adherence of Cyclin-Dependent Kinase 4 and 6 Inhibitors in Patients with Hormone Receptor-Positive Breast Cancer: a Retrospective Observational Study

(014) Assessing Outcomes of Tapering 12-hr and 6-hr Dexamethasone Prior to Paclitaxel Infusions

(015) Assessment of Efficacy and Safety of Hypomethylating agent/Venetoclax versus Cytarabine/Anthracycline (7+3) for Acute Myeloid Leukemia Induction Therapy in 50- to 70-year-old Patients

(016) Assessment of Evidence-Based Pharmacological Therapy for Pediatric Patients with Sickle Cell Disease

(017) Assessment of Infusion Reaction Rates with Rituximab on Day One Versus Day Five or Later for Patients with Newly Diagnosed Aggressive Lymphoma Receiving DA-R-EPOCH (Top Ten Poster)

(018) Assessment of platinum and taxane agent-related infusion reactions before and after vaccination with Coronavirus Disease 2019 (COVID-19) mRNA vaccine

(019) Association analyses of myeloablative busulfan PK and donor chimerism rates among allogenic hematopoietic stem cell transplant recipients

(020) Bendamustine as alternative lymphodepletion for chimeric antigen receptor T-cell (CAR-T) therapy

(021) Bone Modifying Agent Duration in Skeletal Related Events Prevention

(022) Breakthrough CMV Reactivation for Allogeneic Hematopoietic Stem Cell Transplant Patients With or Without Letermovir Prophylaxis

(023) Characteristics and Management of Oxaliplatin Hypersensitivity Reactions

(024) Characterization of Combination Ruxolitinib and Tyrosine Kinase Inhibitors in Allogeneic Hematopoietic Stem Cell Transplant Recipients

(025) Characterization of CTCAE grading of blinatumomab-associated neurotoxicity and the corresponding treatment disruptions

(026) Characterization of Dose-dense Doxorubicin and Cyclophosphamide within the Keynote-522 Trial Regimen for Triple Negative Breast Cancer

(027) Characterization of Treatment Outcomes with Secondary Induction Regimens in TP53-Mutated Newly Diagnosed Acute Myeloid Leukemia Patients

(028) Characterization of VTE Prophylaxis in Multiple Myeloma Patients Receiving Immunomodulator Therapy

(029) Characterizing Hypersensitivity Reactions and Management within an NCI-Designated Comprehensive Cancer Center

(030) Characterizing the Incidence of Arsenic Trioxide Holds and Modifications in Patients with Low Risk Acute Promyelocytic Leukemia and Comorbid Obesity

(031) Cladribine, Low-Dose Cytarabine, and Venetoclax versus Hypomethylating Agent and Venetoclax Induction in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Induction

(032) Clinical Impact of Proton-Pump Inhibitor Therapy in Combination with Certain Tyrosine Kinase Inhibitors in Adult Patients with Chronic Myeloid Leukemia

(033) Clinical Significance of Varicella Titers in the Post Cellular Therapy Setting

(034) Clinical Utility of a Modified Risk Score for Venous Thromboembolism Risk in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

(035) Clofarabine, melphalan and thiotepa reduced-intensity conditioning chemotherapy with post-transplant cyclophosphamide-based graft versus host disease prophylaxis for allogeneic stem cell transplant

(036) Comparative Analysis of FLAG-Ida +/- Venetoclax vs. CLAG-Ida +/- Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

(037) Comparing a Reduced Venetoclax Duration Schema to Conventional Dosing Schema in Patients with Treatment Naïve Acute Myeloid Leukemia

(038) Comparing clinical outcomes associated with two reduced intensity conditioning regimens for allogeneic stem cell transplant (busulfan/clofarabine and busulfan/fludarabine): A retrospective review

(039) Comparing Clinical Outcomes of Abemaciclib in Patients with Hormone Receptor-Positive/HER2-Negative Breast Cancer Filling Through an Internal Specialty Pharmacy versus External Specialty Pharmacies

(040) Comparing the Efficacy and Safety of Gemcitabine + Abraxane (G+A) Versus Gemcitabine + Abraxane + Capecitabine (GAX) in the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

(041) Comparing the Safety and Efficacy of CALGB 10403 and Hyper-CVAD Induction for Acute Lymphoblastic Leukemia in Adults ≥ 40 Years Old

(042) Comparison of Breakthrough Rates of Pneumocystis jiroveci Pneumonia in Adult Patients with Malignancies Receiving Intravenous or Aerosolized Pentamidine for Prophylaxis (Top Ten Poster)

(043) Comparison of Cytomegalovirus Reactivation Rates Based on Day +15 Letermovir Initiation Following Allogeneic Stem Cell Transplant

(044) Comparison of Fludarabine Versus Clofarabine in Combination with Cyclophosphamide and Total Body Irradiation Conditioning Regimens for Allogeneic Bone Marrow Transplantation

(045) Comparison of Graft-Versus-Host Disease- and Relapse-Free Survival of Haploidentical Versus Matched Unrelated Donor Allogeneic Stem Cell Transplants

(046) Comparison of Hemorrhagic Cystitis Rates With and Without Prophylactic Mesna for Cyclophosphamide Cycles in Ewing Sarcoma Patients Receiving VAdriaC/IE

(047) Comparison of Standard Versus Lower Initial Dose of Cabozantinib in Renal Cell Carcinoma and Hepatocellular Carcinoma: A Retrospective Analysis of Tolerability and Clinical Outcomes (Top Ten Poster)

(048) Comparison of Toxicity Profile of Fam-trastuzumab Deruxtecan in HER2+ and HER2-low Metastatic Breast Cancer

(049) Comparison of Weight Gain in Male and Female Patients Treated with Ruxolitinib for Myeloproliferative Neoplasms

(050) Correlates of neuropathy in patients with breast cancer receiving taxane based neoadjuvant or adjuvant chemotherapy

(051) Correlation between COVID vaccinations and infusion-related hypersensitivity reactions with the administration of paclitaxel and docetaxel in patients being treated for gynecologic malignancies

(052) Cost Estimation of Concomitant Venetoclax and Azole Therapies in Patients with Acute Myeloid Leukemia

(053) CPX-351 Induction for Acute Myeloid Leukemia followed by CPX-351 Versus Other Consolidation Chemotherapy

(054) Cytomegalovirus Reactivation Rates: Graft Versus Host Disease Prophylaxis Post-Transplant Cyclophosphamide Based Regimen Compared to Prior Standard of Care

(055) Day 1, 3, 5 vs Day 1, 2, 3 Intermediate to High-dose Cytarabine for Acute Myeloid Leukemia Consolidation Therapy in Patients 60 Years of Age or Greater

(056) Defining and Measuring Trial Activation Metrics for an Oncology Investigational Drug Service Pharmacy

(057) Descriptive Comparison of Oral Chemotherapy Medication Management Programs at an Academic Health System

(058) Development of an Oral Oncology Drug Repository Program at a Tertiary Academic Medical Center

(059) Differences in Time to Count Recovery Between Pegfilgrastim and Filgrastim in Pediatric Patients Receiving Interval Compressed Chemotherapy. (Top Ten Poster)

(060) Documented Dose Modifications of Oral VEGF Tyrosine Kinase Inhibitors in Patients with Clear Cell Renal Cell Cancer

(061) Dose-Limiting Neutropenia with Sacituzumab Govitecan in Adult Patients with Breast Cancer

(062) Early Versus Delayed Initiation of Letermovir Prophylaxis for Cytomegalovirus in High-Risk Allogeneic Stem Cell Transplantation (Top Ten Poster)

(063) Effect of Eltrombopag in Thrombocytopenia after Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

(064) Effects of Concomitant Azoles on Ruxolitinib Treatment in Patients with Acute Graft-Versus-Host-Disease: A Post Hoc Analysis From the Randomized Phase 3 REACH2 Study

(065) Effects of Concomitant Azoles on Ruxolitinib Treatment in Patients with Chronic Graft-Versus-Host-Disease: A Post Hoc Analysis From the Randomized Phase 3 REACH3 Study

(066) Efficacy and Safety of Caplacizumab for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

(067) Efficacy of Capecitabine as Second-Line and Later Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

(068) Efficacy of Immunotherapy Retreatment in Non-Small Cell Lung Cancer Patients Who Received Consolidative Durvalumab

(069) Efficacy of Ipilimumab/Nivolumab vs Standard of Care Chemotherapy for Metastatic Non-Small Cell Lung Cancer Following Chemoimmunotherapy in the First Line Setting

(070) Enoxaparin Dosing for Thromboembolism Prophylaxis in Patients with Obesity and Cancer

(071) Evaluating effects of hypoalbuminemia on tyrosine kinase inhibitors in CML

(072) Evaluating Implementation of a Hospital-Based Cancer Registry to Improve Childhood Cancer Care in Low- and Middle-Income Countries

(073) Evaluating Outpatient-Restricted Medications in the Inpatient Setting for Appropriate Use

(074) Evaluating Safety and Efficacy of Empiric Antimicrobial De-escalation for Febrile Neutropenia in Patients with Malignant Hematology or Undergoing Hematopoietic Stem Cell Transplantation

(075) Evaluating the Effectiveness and Cost of Filgrastim Biosimilar at Loma Linda University Medical Center

(076) Evaluating the Incidence of Febrile Neutropenia Associated with Pegfilgrastim and Filgrastim Use in Patients Greater than 65 Years Old Receiving RCHOP Regimen

(078) Evaluating the Potential Utility of the SAVED Score in Predicting Venous Thromboembolism in a Veteran Cancer Population at VA San Diego

(079) Evaluating the Relationship Between Medication Regimen Complexity & Pharmacist Interventions in a Comprehensive Cancer Center: Utilization of the Medication Regimen Complexity Scoring Tool

(080) Evaluating Tolerability of Concurrent Weekly Cisplatin and Radiation in Geriatric Head and Neck Cancer Patients

(081) Evaluation and Implementation of a Standardized DPYD Testing Protocol for Patients Receiving Fluoropyrimidine-based Chemotherapy in the Medical Oncology Setting

(082) Evaluation and Optimization of Streamlined, Scheduled Chemotherapy Admissions at a Tertiary Hospital

(083) Evaluation of a New Antiemesis Protocol to Reduce Hematopoietic Stem Cell Transplant Associated Nausea and Vomiting

(084) Evaluation of A Pharmacist-Led Service for Refractory and Breakthrough Chemotherapy-Induced Nausea and Vomiting with Highly Emetogenic Chemotherapy

(085) Evaluation of Adverse Reactions Associated with Sacituzumab Govitecan Administered Over Two Infusion Times

(086) Evaluation of an Institutional Hydration Protocol for Post-Transplant Cyclophosphamide in Allogeneic Hematopoietic Stem Cell Transplant Recipients

(087) Evaluation of an investigational drug service concomitant medication review process in oncology clinical trials

(088) Evaluation of Bevacizumab-Related Hypertension and Proteinuria and Treatment Response in Gynecologic Cancer (Top Ten Poster)

(089) Evaluation of Biomarker Testing Practices Across Different Settings of Care for Advanced and Metastatic Gastrointestinal Cancers

(090) Evaluation of carboplatin dose calculations and effects on safety outcomes

(091) Evaluation of Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Serum Creatinine Elevations

(092) Evaluation of Direct Oral Anticoagulant Eligibility and Prescribing for Primary VTE Prevention in High-Risk Ambulatory Cancer Patients

(93) Venetoclax Retreatment In Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

(094) Evaluation of Efficacy and Safety of Eculizumab for the Treatment of Transplant-Associated Thrombotic Microangiopathy (TA-TMA): A Single Center Study

(095) Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2) negative metastatic breast cancer

(096) Evaluation of Fam-trastuzumab Deruxtecan Tolerability in Solid Tumor Patients

(097) Evaluation of Fam-trastuzumab deruxtecan-nxki in Patients with HER2-Low Breast Cancer

(098) Evaluation of Fixed-Dose Rituximab for the Treatment of Non-Malignant Immune-Mediated Hematologic Diseases

(099) Evaluation of Healthcare Resource Utilization Following Initiation of Azacitidine Versus Decitabine in Combination with Venetoclax in Patients with Acute Myeloid Leukemia (Top Ten Poster)

(100) Evaluation of Hyper-CVAD and Mini-CVD Regimens Without Mesna

(101) Evaluation Of Letermovir (Prevymis) For Cytomegalovirus Prevention In Donor Positive, Recipient Negative, Allogeneic Stem Cell Transplant Patients

(102) Evaluation of Non-Adherence to Oral Anticancer Agents in a Medically-Integrated Specialty Pharmacy

(103) Evaluation of PARPi utilization for treatment of prostate cancer at St. Luke’s Cancer Institute

(104) Evaluation of Pharmacogenomic Testing and Tacrolimus Levels

(106) Evaluation of Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate for Graft vs. Host Disease Prophylaxis in Patients Undergoing Allogenic Stem Cell Transplant

(107) Evaluation of Procedural Sedation Outcomes with Dexmedetomidine for Lumbar punctures in Pediatric Oncology Patients

(108) Evaluation of Provider Perception, Utilization, and Barriers to Incorporation of NCCN VTE Prophylaxis Recommendations for Patients with Multiple Myeloma

(109) Evaluation of Risk Factors and Outcomes of Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide

(110) Evaluation of Same-Day vs Next Day Administration of Prophylactic Pegfilgrastim in Fluoropyrimidine-Based GI Cancer Treatment

(111) Evaluation of the Impact of a Pharmacy Resident in an Outpatient Cancer Clinic

(112) Evaluation of the impact of two carboplatin dose calculation methods on overall treatment tolerability in gynecologic oncology patients

(113) Evaluation of the Implementation of High-Dose Methotrexate Management Guidelines

(114) Evaluation of the Incidence and Management of Immune-Related Toxicities in Medical Oncology Patients

(115) Evaluation of the Incidence of Ifosfamide-Induced Neurotoxicity with Concomitant Fosaprepitant in Sarcoma Patients

(116) Evaluation of the Management of Chemotherapy Induced Neutropenia and the Impact on Outcomes in Veterans Receiving Adjuvant FOLFOX for Colon Cancer within the South Texas Veterans Health Care System

(117) Evaluation of Thyroid Toxicity Management Associated with Checkpoint Inhibitor Use

(118) Evaluation of Treatment Tolerability Associated with Carboplatin Dose Based on Actual Body Weight Versus Adjusted Body Weight in Patients with a BMI ≥ 25 mg/m2 with Advanced Ovarian Cancer

(119) Evaluation of Trilaciclib Use and Chemotherapy Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

(120) Financial Impact of Pharmacist-led Toxicity Management in the Oncology Setting

(121) Glucarpi-CAP: A retrospective chart review of 1000 unit glucarpidase dosing for methotrexate rescue

(122) Healthcare Disparities in Lymphoma Patients

(123) High Dose Methotrexate Management: Increasing Efficiencies to Decrease Length of Stay at a Community Hospital

(124) Identification and Evaluation of Evidence-Based Adherence Metrics for Oral Oncolytics: a Systematic Review

(126) Immune Checkpoint Inhibitor Product Placement in Metastatic Non-Small Cell Lung Cancer at a Large Academic Medical Center

(127) Impact of 1.3 mg/m2 versus 1.5 mg/m2 Weekly Bortezomib Dosing within Bortezomib-Lenalidomide-Dexamethasone (VRd) Front-line Induction Therapy for Multiple Myeloma

(128) Impact of a New Hydration Protocol on the Incidence of Cisplatin-Induced Nephrotoxicity

(129) Impact of a Pharmacist-Driven Protocol for High-Dose Methotrexate Monitoring and Leucovorin Rescue

(130) Impact of a Pharmacist-Led Telehealth Toxicity Monitoring Initiative at an Academic Gastrointestinal Oncology Clinic

(132) Impact of Antifungal Use with Post-Transplant Cyclophosphamide on Outcomes Following Allogeneic Hematopoietic Cell Transplant

(133) Impact of Busulfan Pharmacokinetics on Relapse Following Hematopoietic Cell Transplant: A Retrospective Cohort Study

(134) Impact of COVID-19 Infection on Immune Checkpoint Inhibitor Pneumonitis

(135) Impact of Early Relapse on Survival After First-line Therapy in Patients with Peripheral T-cell Lymphomas (Top Ten Poster)

(136) Impact of mitigation strategies to reduce chemotherapy waste during drug shortages at an outpatient infusion center

(137) Impact of Neoadjuvant Therapy on Non-Metastatic Pancreatic Cancer

(138) Impact of Pharmacist-Led Comprehensive Medication Review in an Outpatient Breast Cancer Center

(139) Impact of Pre-emptive Dihydropyrimidine Dehydrogenase Genetic Testing on Clinical Outcomes in Fluoropyrimidine-Naïve Patients

(140) Impact of Premedication on Hypersensitivity and Infusion-Related Reactions Prior to Administration of Pegylated Asparaginase Treatment in Children for Acute Lymphoblastic Leukemia and Lymphoma

(141) Impact of Quadruplet Induction Therapy on Stem Cell Mobilization Yields in Newly Diagnosed Multiple Myeloma

(142) Impact of Removing GCSF on Hematopoietic Allogeneic Stem Cell Transplantation Outcomes

(143) Impact of weekly bortezomib versus twice weekly bortezomib on rates of peripheral neuropathy in combination with lenalidomide, dexamethasone and daratumumab

(144) Implementation and Adherence to Cancer Therapy-Related Cardiovascular Toxicity Monitoring Protocol in Breast Cancer and Gynecologic Oncology Patients

(145) Implementation of a Bispecific T-Cell Engager Therapy Program within a Community Cancer Center

(146) Implementation of a Multigene Pharmacogenomic Testing Pilot within a GI Oncology Clinic

(147) Implementation of a Pharmacist-Driven Pharmacogenomics Dosing Service

(148) Implementation of Best Practice Alerts to Enhance Pharmacist Dose Rounding Compliance of Biologic and Cytotoxic Oncologic Agents Across a Healthcare System

(149) Implementation of Pharmacist Driven Prednisone Dosing in Patients Receiving Abiraterone and/or Docetaxel for Advanced Prostate Cancer

(150) Implementation of Pharmacy Medication Counseling Services for Phase I Investigational Agents

(151) Incidence and Association of Prolonged Cytopenias with Severe Cytokine Release Syndrome Among Patients Undergoing PTCy-Based Haploidentical Stem Cell Transplantation: An Urban Medical Center Analysis

(152) Predictors of Hypomagnesemia with Denosumab in Patients with Metastatic Bone Disease from Solid Malignancies: A Single-Institution Retrospective Study

(153) Incidence and Timing of Ado-Trastuzumab Emtansine Infusion Reactions

(154) Incidence of Chemotherapy Induced Peripheral Neuropathy in Patients Using Cryotherapy Prevention and Receiving Treatment with Taxane-based Chemotherapy

(155) Incidence of Endocrine Toxicities in Patients with Solid Tumor Malignancies Receiving Curative-intent Immune Checkpoint Inhibitor (ICI) Therapy: A Single Institution Experience

(156) Incidence of hypersensitivity and infusion reactions with pegasparaginase using different dosing strategies

(157) Incidence of Hypersensitivity Reactions During and Immediately Following Calaspargase Compared to Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

(158) Incidence of Infusion Related Reactions from Cetuximab During the Observation Period

(159) Incidence of Invasive Fungal Disease and Viral Infections in Pediatric Patients Treated with Targeted Agents for Graft versus Host Disease

(160) Incidence of Paclitaxel Hypersensitivity Reactions at an Academic Community Hospital System

(161) Incidence of Paclitaxel Infusion-Related Reactions with Two Low-Dose Dexamethasone Premedication Strategies in Breast Cancer Patients

(162) Incidence of PARP Inhibitor Toxicities Between Germline Versus Somatic Homologous Recombination Mutations

(163) Infectious Complications Following Chimeric Antigen Receptor T-Cell Therapy

(164) Influence of Patient Residence on Long-term Outcomes of Acute Lymphoblastic Leukemia Treatment at an Academic Medical Center

(165) Investigating the cardio-oncology patient population at a large, multi-site health system: a descriptive analysis

(166) Investigating the Impact of Concurrent Ototoxic Drugs on Cisplatin-Induced Ototoxicity in Pediatric Cancer

(167) Investigating the Impact of Daratumumab on Rates of Infections and VTE among Multiple Myeloma Patients Treated with Dara-RVd vs. RVd

(168) Is It Time to BAG the Old Ways of MAG? Decrease Infusion Time of IV Magnesium to Improve Patient Care

(169) Lipid Monitoring Practice for Patients with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

(170) Management of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Solid Tumor Patients at an Academic Medical Center

(171) Meperidine compared to morphine for treatment of rigors associated with monoclonal antibody-related infusion reactions

(172) Model-Informed Precision Dosing of Fludarabine for Adult CAR-T Lymphodepletion

(173) Olanzapine for Primary Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Autologous Stem Cell Transplant

(174) Oncology Pharmacist Productivity Tool Implementation in a Clinic Setting (OPTICS)

(175) Oncology Pharmacist-Initiated Tyrosine Kinase Inhibitor Discontinuation and Monitoring Clinic in Veterans with Chronic Myeloid Leukemia within Veterans Integrated Services Network 17

(176) Optimization of Daratumumab Based Treatment Plans

(177) Optimization of Venetoclax Dosing with Posaconazole Prophylaxis in Acute Myeloid Leukemia

(178) Oral breast cancer therapy interventions in an integrated health system: Analysis of patient acceptance rate of clinical specialty pharmacist interventions during medication consultations

(179) Outcomes in Early-Stage Triple Negative Breast Cancer with Dose-Dense AC as Part of Pembrolizumab Based Regimens

(180) Outcomes in Patients with Aplastic Anemia Treated with Horse Anti-thymocyte Globulin and/or Stem Cell Transplantation at an Academic Medical Center (Top Ten Poster)

(181) Outcomes of Alemtuzumab or Post Transplant Cyclophosphamide-based Graft-Versus-Host-Disease Prophylaxis in Adult Patients with Allogeneic Hematopoietic Stem Cell Transplantation

(182) Outpatient management of bispecific related toxicities: an observational study of safety outcomes and resource utilization

(183) Outpatient Supportive Care Optimization for Patients Experiencing Chemotherapy Toxicity with Preventable Admissions

(184) Patterns of Frontline Treatment Among Older Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

(185) Pharmacokinetic Summary and Toxicities of Calaspargase Pegol in Pediatric Patients

(186) Pneumocystis jirovecii pneumonia in patients receiving brentuximab-based chemotherapy

(187) Post-Transplant Cyclophosphamide in Unrelated Donor Allogeneic Stem Cell Transplantation with Reduced Intensity and Nonmyeloablative Conditioning Regimens for Graft-Versus-Host Disease Prophylaxis

(188) Post-transplant cyclophosphamide is associated with reduced aGVHD and improved clinical outcomes among allogeneic hematopoietic transplant recipients

(189) Post-Transplant Cyclophosphamide vs. Alemtuzumab for Graft-versus-Host Disease Prophylaxis

(190) Predicted Fludarabine Exposure Impact on Clinical Outcomes After CAR-T Therapy for Lymphomas

(191) Predictors of Delayed Methotrexate Clearance in Patients Receiving High-Dose Methotrexate Based Regimens for Primary Central Nervous System Lymphoma

(192) Prevalence of Anticancer Agents Used in Cancer Treatment in Current Practice

(193) Rapid Rituximab Protocol Evaluation and Expansion

(194) Rates of Cardiotoxicity in Patients Receiving Chemo-immunotherapy with Anthracyclines Compared to Chemotherapy with Anthracyclines Alone

(195) Real World Clinical Outcomes in Patients Receiving Capmatinib or Tepotinib in MET altered NSCLC

(196) Real World Comparison of the Efficacy and Safety of Atezolizumab versus Durvalumab in Extensive Stage Small Cell Lung Cancer

(197) Real world efficacy and tolerability of axitinib + pembrolizumab in the treatment of renal cell carcinoma

(198) Real World Experience of Breakthrough Invasive Fungal Infections on Isavuconazole vs. Posaconazole in Malignant Hematology Patients

(199) Real World Outcomes of Patients Receiving Immune Checkpoint Inhibitors in the Inpatient Setting

(200) Real-World Analysis of Adjuvant Abemaciclib in High-Risk HR+/HER2- Early-Stage Breast Cancer

(201) Real-World Analysis of Alternate Treatments During the Fludarabine Shortage

(202) Real-World Comparative Evaluation of Ibrutinib, Acalabrutinib, and Zanubrutinib Tolerability in Patients with Chronic Lymphocytic Leukemia

(204) Real-World Outcomes Associated with Subsequent-Line Therapy for Metastatic Renal Cell Carcinoma: An Institution’s Experience

(205) Real-World Retrospective Review: Investigating Cardiac Toxicity in Breast Cancer Patients Undergoing Capecitabine Therapy with and without DPYD Mutations - A Cardio-Oncology and Pharmacogenomic Study

(206) Remission Rates at End of Induction with HyperCVAD versus CALGB 19802 in Adult Acute Lymphoblastic Leukemia Patients

(207) Review of rasburicase utilization for prevention of tumor lysis syndrome in malignant hematology patients

(208) Rhythm and Rhyme Behind "POEM" Pharmacist Involvement with Oral Anticancer Agents

(209) Risk Factors for Primary Refractory Disease in Patients with Advanced Biliary Tract Cancer Treated with First Line Chemotherapy

(210) Safety and Efficacy of First-Line Therapy for Advanced/Metastatic Lung Cancer in Veterans

(211) Safety and Efficacy of Romiplostim in Maintaining Chemotherapy Interval and Dose Intensity in Pediatric Patients with Solid Tumors and Chemotherapy Induced Thrombocytopenia (CIT)

(212) Safety and Efficacy of Voriconazole versus Posaconazole Antifungal Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndrome

(213) Safety and Tolerability of Adjuvant Combination Treatments following Keynote-522 for Early-Stage/Locally Advanced Breast Cancer with Residual Disease

(214) Safety of Bridging Regimens Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients With Primary and Secondary CNS Lymphoma (Top Ten Poster)

(215) Safety of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia in Blast Phase

(216) Safety of Venetoclax in Combination with a Hypomethylating Agent for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Hospitalized Patients

(217) Outcomes of Reduced Dosing of Lenvatinib with Pembrolizumab for Advanced Endometrial Cancer

(218) Safety Outcomes of Teclistamab Accelerated Dose Escalation

(219) Short course cefixime for the prevention of irinotecan-associated diarrhea in children with solid tumors

(220) Single-Center Pediatric Experience With BRAF-and/orMEK-Inhibitors for Treatment of Pediatric Glioma

(221) Spill the Genes! Frequency of high-risk phenotypes and pharmacogenomically actionable medication use in pediatric patients with cancer

(222) Standardizing Minimum Residual Disease Testing in an Ambulatory Hematology/Oncology Clinic

(223) Tacrolimus Time in Therapeutic Range after Hematopoietic Stem Cell Transplantation

(224) Taking a BiTE® into CRS Management: Cytokine Release Syndrome Management for Bispecific T Cell Engager Therapies

(225) The Analysis of Fms-like Tyrosine Kinase Inhibitor Maintenance Therapy Following Allogeneic Stem Cell Transplant in Patients with Fms-like Tyrosine Kinase-mutated Acute Myeloid Leukemia

(227) The Impact of Concomitant High-Dose Corticosteroids and Immune Checkpoint Inhibitors in Patients with Brain Metastases Secondary to Lung Cancer or Melanoma

(228) The Impact of Virtual Education on Patient and Caregiver Understanding of Chemotherapy Regimens (TEACH)

(229) The Utility of Pharmacogenomics in Adult Bone Marrow Transplantation

(230) Time is of the Essence: Reduced Venetoclax Duration in Patients with Acute Myeloid Leukemia

(231) Time to Resolution of Grade 1 Cytokine Release Syndrome With or Without Interleukin-6 Receptor Antagonist Therapy

(232) Time to Therapeutic Decision in NSCLC: A Comparative Study of Liquid and Tissue Biopsies

(233) Tolerability and Safety of a 3-step or 12-step Chemotherapy Desensitization Protocol

(234) Transplant-Related Mortality in Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation: Fludarabine/Melphalan, Fludarabine/Busulfan, Clofarabine/Busulfan

(235) Understanding and Managing Oral VEGF Inhibitor Toxicities in Renal Cell Carcinoma

(236) Use of Venetoclax in Combination with Hypomethylating Agents for the Treatment of Myelodysplastic Syndrome

(237) Use of Venetoclax Plus Cladribine, Idarubicin, and Cytarabine as Induction Chemotherapy for De Novo or Relapsed/Refractory Acute Myeloid Leukemia: A Single Center Experience

(238) Using A Digital Health Device to Reduce Time Monitoring Patients on Acalabrutinib

(239) Utility of Thrombopoietin Receptor Agonists (TPO-RAs) for Prolonged Thrombocytopenia After CAR-T Cell Therapy